CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
Exciting results for the use of Zanidatamab in first line treatment for GEA has been presented at the 2026 ASCO GI Symposium. HERIZON-GEA-01 was a global, randomized phase 3 study evaluating zanidatamab plus chemotherapy (with or without PD-1 inhibition) versus trastuzumab plus chemotherapy as first-line treatment for HER2-positive locally advanced unresectable or metastatic GEA. The study results establish zanidatamab as a high-activity HER2-targeted agent in mGEA and support its role as a key component of HER2-directed therapy.
The Breast International Group (BIG) informs its community and supporters of an important organisational development. After over 25 years of dedicated work, and despite exploring every possible avenue to ensure long-term sustainability, BIG now faces financial constraints that can no longer be overcome.
CCTG is happy to announce the launch of the new Investigator Leadership Mentoring and Training (VISION) program. As part of our mandate to support training and education within the network, this program aims to provide CCTG investigators the opportunity to enhance their leadership skills through interactive, expert-facilitated workshops.
Congratulations to Dr. Simron Singh who was named as Chair in Neuroendocrine Medical and Systemic Cancer Care & Research, jointly shared by Sunnybrook Health Sciences Centre and the University of Toronto’s Temerty Faculty of Medicine. As Chair he will support a combination of clinical trial innovation, precision biomarker discovery, and translational research integration at Sunnybrook.
The 2026 ASCO Gastrointestinal Cancer Symposium was held on January 8-10, 2026 in San Francisco, California see all the CCTG Abstracts below.
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) and led by Canadian Cancer Trials Group (CCTG), were published in the Journal of Clinical Oncology.
